<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="crossover of animal Betacoronaviruses to humans has resulted in severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome"/>
 <result pre="of animal Betacoronaviruses to humans has resulted in severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus"/>
 <result pre="animal Betacoronaviruses to humans has resulted in severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)."/>
 <result pre="in severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV). In December 2019, a global public"/>
 <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV). In December 2019, a global public health"/>
 <result pre="(HCoVs), HCoV-OC43 and HCoV-HKU1. The fatality rate of SARS-CoV-2 is" exact="lower" post="than the two previous coronavirus epidemics, but it is"/>
 <result pre="spreading and the large number of infected people with severe" exact="viral pneumonia" post="and respiratory illness, showed SARS-CoV-2 to be highly contagious."/>
 <result pre="and the large number of infected people with severe viral" exact="pneumonia" post="and respiratory illness, showed SARS-CoV-2 to be highly contagious."/>
 <result pre="large number of infected people with severe viral pneumonia and" exact="respiratory" post="illness, showed SARS-CoV-2 to be highly contagious. Based on"/>
 <result pre="manifestations, preventions, diagnosis and up to date treatments of SARS-CoV-2" exact="infections" post="in comparison with those caused by SARS-CoV and MERS-CoV."/>
 <result pre="as therapeutic approaches. SARS-CoV-2 epidemiology transmission temperature and humidity COVID-19" exact="pneumonia" post="diagnosis ACE2 inhibitors therapeutics strategies 1. Introduction 1.1. What"/>
 <result pre="can infect animals [1,2] and humans, leading to 5â€&quot;10% of" exact="acute" post="respiratory syndromes [3]. Apart from infecting a variety of"/>
 <result pre="infect animals [1,2] and humans, leading to 5â€&quot;10% of acute" exact="respiratory" post="syndromes [3]. Apart from infecting a variety of economically"/>
 <result pre="pigs and chickens), six species have been identified to cause" exact="disease" post="in humans [4]. They are known to infect respiratory,"/>
 <result pre="wide range of clinical features from asymptomatic course to severe" exact="disease" post="that require hospitalization in the intensive care unit [4,5]."/>
 <result pre="human coronaviruses (HCoVs), HCoV-229E and OC43, shown to be significant" exact="respiratory" post="pathogens, were identified in the 1960s [6,7]. However, it"/>
 <result pre="[6,7]. However, it is assumed that the first recorded coronavirus-related" exact="disease" post="was feline infectious peritonitis (FIP) in 1912 [8]. The"/>
 <result pre="is assumed that the first recorded coronavirus-related disease was feline" exact="infectious" post="peritonitis (FIP) in 1912 [8]. The â€œcoronaâ€�-like or crown-like"/>
 <result pre="assumed that the first recorded coronavirus-related disease was feline infectious" exact="peritonitis" post="(FIP) in 1912 [8]. The â€œcoronaâ€�-like or crown-like morphology"/>
 <result pre="infectious peritonitis (FIP) in 1912 [8]. The â€œcoronaâ€�-like or crown-like" exact="morphology" post="of these viruses leads to choose the name â€œcoronavirus,â€�"/>
 <result pre="the 21st century. Afterward, two highly pathogenic HCoVs, including severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome"/>
 <result pre="21st century. Afterward, two highly pathogenic HCoVs, including severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus"/>
 <result pre="century. Afterward, two highly pathogenic HCoVs, including severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV),"/>
 <result pre="including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), emerging from animal reservoirs, have led"/>
 <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), emerging from animal reservoirs, have led to"/>
 <result pre="from animal reservoirs, have led to global epidemics of deadly" exact="pneumonia" post="in humans with high morbidity and mortality [9,10]. In"/>
 <result pre="the capital city of Hubei province in China, causing severe" exact="pneumonia" post="[11,12]. Considered as agents that are a great public"/>
 <result pre="and this new coronavirus was named SARS-CoV-2 and the related" exact="respiratory" post="disease COVID-19 (https://www.who.int). Compared with SARS-CoV, SARS-CoV-2 appears to"/>
 <result pre="this new coronavirus was named SARS-CoV-2 and the related respiratory" exact="disease" post="COVID-19 (https://www.who.int). Compared with SARS-CoV, SARS-CoV-2 appears to be"/>
 <result pre="dogs and cats [18,19]. Animal CoVs are known to cause" exact="acute" post="diseases in several animals and could be responsible for"/>
 <result pre="birds [20,21]. Domestic animals may play an important role as" exact="intermediate" post="hosts that enable virus transmission from one species to"/>
 <result pre="can also infect mammals [16]. These animal CoVs include transmissible" exact="gastroenteritis" post="virus (TGEV), porcine epidemic diarrhea virus (PEDV), avian infectious"/>
 <result pre="These animal CoVs include transmissible gastroenteritis virus (TGEV), porcine epidemic" exact="diarrhea" post="virus (PEDV), avian infectious bronchitis virus (IBV)â€&quot;and more recentlyâ€&quot;swine"/>
 <result pre="transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), avian" exact="infectious" post="bronchitis virus (IBV)â€&quot;and more recentlyâ€&quot;swine acute diarrhea syndrome coronavirus"/>
 <result pre="gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), avian infectious" exact="bronchitis" post="virus (IBV)â€&quot;and more recentlyâ€&quot;swine acute diarrhea syndrome coronavirus (SADS-CoV)."/>
 <result pre="diarrhea virus (PEDV), avian infectious bronchitis virus (IBV)â€&quot;and more recentlyâ€&quot;swine" exact="acute" post="diarrhea syndrome coronavirus (SADS-CoV). However, animal CoVs can also"/>
 <result pre="virus (PEDV), avian infectious bronchitis virus (IBV)â€&quot;and more recentlyâ€&quot;swine acute" exact="diarrhea" post="syndrome coronavirus (SADS-CoV). However, animal CoVs can also infect"/>
 <result pre="(PEDV), avian infectious bronchitis virus (IBV)â€&quot;and more recentlyâ€&quot;swine acute diarrhea" exact="syndrome" post="coronavirus (SADS-CoV). However, animal CoVs can also infect humans"/>
 <result pre="animal CoVs can also infect humans that can spread the" exact="infection" post="through human-to-human transmission [17,22]. On the other hand, Alpha-"/>
 <result pre="hand, Alpha- and Betacoronavirus infect only mammals and usually cause" exact="respiratory" post="illness in humans; among these, strains 229E, OC43, HKU1"/>
 <result pre="by sequential mutations and recombination, including those occurring in the" exact="intermediate" post="hosts, civets and raccoon dogs for SARS-CoV and camels"/>
 <result pre="originated in bats and that pangolins (Manis javanica) acted as" exact="intermediate" post="mammalian hosts [11,27] (Figure 2). Indeed, the genetic sequence"/>
 <result pre="oculo-oronasal infections, more evidences are needed to exclude pigs as" exact="intermediate" post="host of SARS-CoV-2 [29]. Based on the genetic sequence"/>
 <result pre="(E), a membrane protein (M) and nucleocapsid protein (N) with" exact="short" post="untranslated regions at both termini, required to produce a"/>
 <result pre="untranslated regions at both termini, required to produce a structurally" exact="complete" post="viral particle [37]. The typical coronavirus virion structure and"/>
 <result pre="regions at both termini, required to produce a structurally complete" exact="viral" post="particle [37]. The typical coronavirus virion structure and proteins"/>
 <result pre="help tether the genome to replicationâ€&quot;transcription complex (RTC) and package" exact="viral" post="RNA into the viral particle during viral assembly [39,40]."/>
 <result pre="to replicationâ€&quot;transcription complex (RTC) and package viral RNA into the" exact="viral" post="particle during viral assembly [39,40]. The E protein is"/>
 <result pre="(RTC) and package viral RNA into the viral particle during" exact="viral" post="assembly [39,40]. The E protein is involved in virus"/>
 <result pre="protein plays a vital role in attachment to host receptors," exact="viral" post="entry and determines host tropism [41,42]. Additionally, some coronaviruses,"/>
 <result pre="and Life Cycle of HCoVs Attachment, cell entry, translation of" exact="viral" post="replicase, genome replication, translation of structural proteins and virion"/>
 <result pre="different host receptors to gain entry into host cells [4,51,52]." exact="Viral" post="entry is mediated by the transmembrane S glycoprotein that"/>
 <result pre="receptor; however, the S2 domain mediates the fusion events, between" exact="viral" post="envelope and host cell membrane [52,55,56]. As recently found,"/>
 <result pre="the plasma membrane of host cell generates a double membrane" exact="vesicle" post="in the host cell, thereby allowing release of the"/>
 <result pre="MERS-CoV, but also that they can use other species as" exact="intermediate" post="hosts before spreading to humans [59,60]. The detection of"/>
 <result pre="â€˜jumpedâ€™ the barrier of the species to infect pigs as" exact="intermediate" post="hosts. The CD26 receptor sequence alignment between humans and"/>
 <result pre="that pigs are susceptible to human SARS-CoV [64] and MERS-CoV" exact="infections" post="[65]. The large number of mutations within the RBD"/>
 <result pre="outbreak [15]. Hence, COVID-19 should be considered as a zoonotic" exact="disease" post="that spread from animals to humans. Following the first"/>
 <result pre="first SARS-CoV-2 outbreak in seafood and wildlife market in Wuhan," exact="secondary" post="cases started to be identified after ten days. Although"/>
 <result pre="January 13, 2020, Thailand announced the first non-Chinese case of" exact="infection" post="that spread from the Chinese provinces, to the Asian"/>
 <result pre="by using phylogenetic analysis based on nucleotide mutations of 160" exact="complete" post="human SARS-CoV-2 genomes found that three variants of SARS-CoV-2"/>
 <result pre="the A and C types were found mostly in European-" exact="American" post="patients, whereas the B type was common in East"/>
 <result pre="in following the evolution of SARS-CoV-2 [67]. Human-to-Human Transmission and" exact="Viral" post="Reservoir It was demonstrated that SARS-CoVs have adapted themselves"/>
 <result pre="to efficiently bind to human ACE2, thus infecting ciliated bronchial" exact="epithelial" post="cells and type II pneumocytes [15,69]. Similar to SARS-CoV,"/>
 <result pre="to human ACE2, thus infecting ciliated bronchial epithelial cells and" exact="type II" post="pneumocytes [15,69]. Similar to SARS-CoV, ACE2 is also used"/>
 <result pre="powerful infectivity of SARS-CoV-2 is that the shedding pattern of" exact="viral" post="particles in SARS-CoV-2 diagnosed patients is similar to that"/>
 <result pre="patients is similar to that of influenza patients in which" exact="viral" post="loads at the time of symptom onset are higher"/>
 <result pre="more easily than SARS-CoV in the community even in the" exact="absence of" post="symptoms or when only initial mild symptoms are present"/>
 <result pre="The human-to-human transmission of SARS-CoV-2 mainly occurs by inhalation of" exact="respiratory" post="droplets spread by coughing or sneezing from an infected"/>
 <result pre="mouth and eyes [24,76,77,78]. The virus was shown to remain" exact="stable" post="in favorable atmospheric conditions on different surfaces for days"/>
 <result pre="the virus. Studies have also indicated that SARS-CoV-2 transmission via" exact="ocular" post="surfaces should not be overlooked, as contaminated droplets and"/>
 <result pre="transmission during vaginal birth can occur remains to be established," exact="neonatal" post="COVID-19 disease as postnatal transmission was documented [83]. Although,"/>
 <result pre="vaginal birth can occur remains to be established, neonatal COVID-19" exact="disease" post="as postnatal transmission was documented [83]. Although, SARS-CoV-2 may"/>
 <result pre="neonates, infants and children develop significantly milder forms of the" exact="disease" post="than their adult counterparts [24,84]. 3. Epidemiology Coronaviruses are"/>
 <result pre="children develop significantly milder forms of the disease than their" exact="adult" post="counterparts [24,84]. 3. Epidemiology Coronaviruses are responsible for 5â€&quot;10%"/>
 <result pre="counterparts [24,84]. 3. Epidemiology Coronaviruses are responsible for 5â€&quot;10% of" exact="acute" post="respiratory illness while it has been estimated that 2%"/>
 <result pre="[24,84]. 3. Epidemiology Coronaviruses are responsible for 5â€&quot;10% of acute" exact="respiratory" post="illness while it has been estimated that 2% of"/>
 <result pre="these viruses. The first discovered HCoV was IBV that causes" exact="respiratory" post="disease in human whereas, HCoV-229E and HCoV-OC43, which cause"/>
 <result pre="viruses. The first discovered HCoV was IBV that causes respiratory" exact="disease" post="in human whereas, HCoV-229E and HCoV-OC43, which cause the"/>
 <result pre="in December 2019, there were reports of patients presenting severe" exact="viral pneumonia" post="[15,88,89]. This public health concern resulted in many unknown"/>
 <result pre="December 2019, there were reports of patients presenting severe viral" exact="pneumonia" post="[15,88,89]. This public health concern resulted in many unknown"/>
 <result pre="pneumonia [15,88,89]. This public health concern resulted in many unknown" exact="pneumonia" post="cases who were admitted to local hospitals [22,78] (https://www.who.int)."/>
 <result pre="pneumonia cases who were admitted to local hospitals [22,78] (https://www.who.int)." exact="Primary" post="etiologic investigations performed in those patients showed that they"/>
 <result pre="new type of coronavirus was isolated [60,91]. The epicenter of" exact="infection" post="was probably linked to a zoonotic pathogen being present"/>
 <result pre="indicated a second mode of transmission, from human-to-human, that allowed" exact="viral" post="spreading primarily in other Asian countries such as South"/>
 <result pre="These favorable conditions caused the wide transmission of this fatal" exact="pneumonia" post="and severe difficulties for disease control and prevention of"/>
 <result pre="wide transmission of this fatal pneumonia and severe difficulties for" exact="disease" post="control and prevention of the epidemic [92]. Based on"/>
 <result pre="Conditions on the Transmission of SARS-CoV-2 The transmission of seasonal" exact="respiratory" post="coronaviruses can be affected by several climate parameters such"/>
 <result pre="average amount of humidity is very close between European and" exact="African" post="selected sites. The main reason is the proximity of"/>
 <result pre="main reason is the proximity of these cities to the" exact="Mediterranean" post="Sea coastline. In addition, the north wind, which blows"/>
 <result pre="Conversely, there are temperature differences between considered ECs and North" exact="African" post="cities (Table 3). Thus, temperature and humidity should be"/>
 <result pre="of 1 Â°C in temperature and 1% in relative humidity" exact="lower" post="R by 0.0225 and 0.0158, respectively [98]. A preprint"/>
 <result pre="increase in the minimum temperature of higher-temperature cities reduced the" exact="disease" post="incidence and death rates by 0.86 [99]. Another preprint"/>
 <result pre="below 78% which may comodulate the infectivity of SARS-CoV-2 within" exact="respiratory" post="droplets [103]. Overall, these meteorological analyses support that the"/>
 <result pre="and humidity may help to predict the prevalence of this" exact="disease" post="in terms of environmental characteristics. This could lead to"/>
 <result pre="The most common symptoms of patients at onset of COVID-19" exact="disease" post="are defined as fever, dry cough, fatigue and less"/>
 <result pre="symptoms of sputum production, headache, sore throat, myalgia; hemoptysis, dyspnea," exact="diarrhea" post="and lymphopenia were also observed [15,24,28] (Figure 6). The"/>
 <result pre="sputum production, headache, sore throat, myalgia; hemoptysis, dyspnea, diarrhea and" exact="lymphopenia" post="were also observed [15,24,28] (Figure 6). The spectrum of"/>
 <result pre="has been found ranging from an asymptomatic state to severe" exact="respiratory" post="failure and multiorgan dysfunction [24,76]. Symptomatic people are considered"/>
 <result pre="are considered to be more contagious, similar to most viral-related" exact="respiratory" post="diseases. However, individuals who remain asymptomatic may also transmit"/>
 <result pre="prodrome period of COVID-19 have also been reported [76]. Asymptomatic" exact="infections" post="can occur because of weakened immune responses and subclinical"/>
 <result pre="invade and reproduce. A recent study has shown that a" exact="viral" post="load detected in an asymptomatic patient was just like"/>
 <result pre="asymptomatic patient was just like to the one observed in" exact="symptomatic" post="patients, indicating the capability of transmission in asymptomatic patients"/>
 <result pre="the capability of transmission in asymptomatic patients [74]. According to" exact="disease" post="presentation, COVID-19 can be classified as mild, moderate, severe"/>
 <result pre="severe and critical (Table 4) [57,76,105]. The symptoms of SARS-CoV-2" exact="infection" post="appear after an incubation period of 1 to 14"/>
 <result pre="to 14 days, similar to those of SARS- and MERS-CoV" exact="infections" post="(median approximately 5.2 days in different studies) and 95%"/>
 <result pre="5 days, 7 days for hospitalization and 8 days for" exact="acute" post="respiratory distress syndrome (ARDS) (Figure 7) [24] (https://www.epicentro.iss.it/coronavirus/sars-cov-2). Patients"/>
 <result pre="days, 7 days for hospitalization and 8 days for acute" exact="respiratory" post="distress syndrome (ARDS) (Figure 7) [24] (https://www.epicentro.iss.it/coronavirus/sars-cov-2). Patients at"/>
 <result pre="days for hospitalization and 8 days for acute respiratory distress" exact="syndrome" post="(ARDS) (Figure 7) [24] (https://www.epicentro.iss.it/coronavirus/sars-cov-2). Patients at this stage"/>
 <result pre="unit (ICU) with quarantine facilities may require mechanical ventilation. Moreover," exact="bacterial infections" post="can cause a secondary pneumonia [108]. In addition, the"/>
 <result pre="(ICU) with quarantine facilities may require mechanical ventilation. Moreover, bacterial" exact="infections" post="can cause a secondary pneumonia [108]. In addition, the"/>
 <result pre="may require mechanical ventilation. Moreover, bacterial infections can cause a" exact="secondary" post="pneumonia [108]. In addition, the period from the beginning"/>
 <result pre="require mechanical ventilation. Moreover, bacterial infections can cause a secondary" exact="pneumonia" post="[108]. In addition, the period from the beginning of"/>
 <result pre="with underlying health problems, SARS-CoV-2 is able to infect the" exact="lower" post="respiratory tract leading to severe pneumonia [111]. In 25â€&quot;30%"/>
 <result pre="underlying health problems, SARS-CoV-2 is able to infect the lower" exact="respiratory" post="tract leading to severe pneumonia [111]. In 25â€&quot;30% of"/>
 <result pre="able to infect the lower respiratory tract leading to severe" exact="pneumonia" post="[111]. In 25â€&quot;30% of patients presenting acute lung injury,"/>
 <result pre="leading to severe pneumonia [111]. In 25â€&quot;30% of patients presenting" exact="acute" post="lung injury, shock, ARDS and acute kidney injury, ICU"/>
 <result pre="25â€&quot;30% of patients presenting acute lung injury, shock, ARDS and" exact="acute" post="kidney injury, ICU admission was absolutely required [24]. Recovery"/>
 <result pre="of patients presenting acute lung injury, shock, ARDS and acute" exact="kidney injury," post="ICU admission was absolutely required [24]. Recovery started within"/>
 <result pre="with 2 and 61.4% with 3 or more (https://www.epicentro.iss.it/coronavirus/sars-cov-2). SARS-CoV-2" exact="infections" post="revealed some unique clinical characteristics that include targeting the"/>
 <result pre="infections revealed some unique clinical characteristics that include targeting the" exact="lower" post="airway which is evident by symptoms of upper respiratory"/>
 <result pre="targeting the lower airway which is evident by symptoms of" exact="upper" post="respiratory tract including rhinorrhoea, sneezing and sore throat [78]."/>
 <result pre="the lower airway which is evident by symptoms of upper" exact="respiratory" post="tract including rhinorrhoea, sneezing and sore throat [78]. Chest"/>
 <result pre="and sore throat [78]. Chest computed tomography (CT) scans revealed" exact="pneumonia" post="in most SARS-CoV-2 infected patients and several cases showed"/>
 <result pre="infected patients and several cases showed an infiltrate in the" exact="upper" post="lung lobe, which is related to increasing dyspnea with"/>
 <result pre="Table 4 describes the full picture of COVID-19 clinical manifestation." exact="Atypical" post="symptoms include RNAemia, acute cardiac injury, ARDS and grand-glass"/>
 <result pre="full picture of COVID-19 clinical manifestation. Atypical symptoms include RNAemia," exact="acute" post="cardiac injury, ARDS and grand-glass opacities that lead to"/>
 <result pre="that COVID-19 manifestations such as fever, dyspnea, dry cough and" exact="bilateral" post="ground-glass opacities in chest CT scans are similar to"/>
 <result pre="as fever, dyspnea, dry cough and bilateral ground-glass opacities in" exact="chest" post="CT scans are similar to the previous Betacoronavirus-related diseases"/>
 <result pre="the previous Betacoronavirus-related diseases [113,114]. Although gastrointestinal symptoms such as" exact="diarrhea" post="were reported in SARS-CoV-2 infected patients, the similar gastrointestinal"/>
 <result pre="cases were characterized by an increased inflammation due to both" exact="systemic" post="and localized immune response activation [78,115]. Higher leukocyte numbers,"/>
 <result pre="characterized by an increased inflammation due to both systemic and" exact="localized" post="immune response activation [78,115]. Higher leukocyte numbers, significantly high"/>
 <result pre="detecting specific clinical signs and symptoms in COVID-19 patients. Moreover," exact="atypical" post="manifestations revealed by pulmonary imaging [116] and the huge"/>
 <result pre="and symptoms in COVID-19 patients. Moreover, atypical manifestations revealed by" exact="pulmonary" post="imaging [116] and the huge number of different clinical"/>
 <result pre="in clinical diagnosis, the application of high-throughput sequencing technology is" exact="limited" post="due to high cost and its equipment dependency [114,120,121]."/>
 <result pre="of standardized analytic kits for diagnostic application, the quantification of" exact="viral" post="load was not considered. Therefore, the RT-PCR method was"/>
 <result pre="chosen as the gold standard for the detection of SARS-CoV-2" exact="infections" post="from the commonly used samples such as naso- and"/>
 <result pre="of those protocols are mentioned below. The US centers for" exact="disease" post="control and prevention (CDC) developed an RT-PCR that includes"/>
 <result pre="extraction and retro-transcription. Moreover, the positive control consisting in retro-transcribed" exact="viral" post="RNA is also available at CDC. To report the"/>
 <result pre="three N regions must be positive. The Chinese Center for" exact="Disease" post="Control and Prevention (China CDC) recommends the use of"/>
 <result pre="Allplex 2019-nCoV (Seegene, Seoul, South Korea) which includes three different" exact="viral" post="targets and a positive control [124]. Another example is"/>
 <result pre="Cambridge, MA, USA). Both companies declared a sensibility of 100â€&quot;150" exact="viral" post="copies per mL and a high specificity that excludes"/>
 <result pre="copies per mL and a high specificity that excludes most" exact="respiratory" post="tract viral and bacterial pathogens. The recommended samples for"/>
 <result pre="mL and a high specificity that excludes most respiratory tract" exact="viral" post="and bacterial pathogens. The recommended samples for both in-house"/>
 <result pre="a high specificity that excludes most respiratory tract viral and" exact="bacterial" post="pathogens. The recommended samples for both in-house and ready-to-use"/>
 <result pre="recommended samples for both in-house and ready-to-use RT-PCR kits include" exact="upper" post="and lower respiratory specimens such as throat, nasal nasopharyngeal"/>
 <result pre="for both in-house and ready-to-use RT-PCR kits include upper and" exact="lower" post="respiratory specimens such as throat, nasal nasopharyngeal (NP) and/or"/>
 <result pre="both in-house and ready-to-use RT-PCR kits include upper and lower" exact="respiratory" post="specimens such as throat, nasal nasopharyngeal (NP) and/or oropharyngeal"/>
 <result pre="such as throat, nasal nasopharyngeal (NP) and/or oropharyngeal (OP) swabs," exact="lower" post="respiratory tract aspirates, sputum, bronchoalveolar lavage (BAL) fluid and"/>
 <result pre="as throat, nasal nasopharyngeal (NP) and/or oropharyngeal (OP) swabs, lower" exact="respiratory" post="tract aspirates, sputum, bronchoalveolar lavage (BAL) fluid and nasopharyngeal"/>
 <result pre="or nasal aspirate. It was observed that samples of the" exact="lower" post="respiratory tract provide the higher viral loads [74]. On"/>
 <result pre="nasal aspirate. It was observed that samples of the lower" exact="respiratory" post="tract provide the higher viral loads [74]. On the"/>
 <result pre="that samples of the lower respiratory tract provide the higher" exact="viral" post="loads [74]. On the other hand, it was shown"/>
 <result pre="it was extensively reported that in the presence of low" exact="viral" post="load this technique fails in detecting viral genome leading"/>
 <result pre="presence of low viral load this technique fails in detecting" exact="viral" post="genome leading to false negative results [126]. Due to"/>
 <result pre="missed diagnosis. Clinicians have demonstrated the usefulness of CT and" exact="chest" post="radiography for the diagnosis of COVID-19 associated pneumonia [128]."/>
 <result pre="CT and chest radiography for the diagnosis of COVID-19 associated" exact="pneumonia" post="[128]. Moreover, the ability of radiologists to diagnose COVID-19"/>
 <result pre="pneumonia [128]. Moreover, the ability of radiologists to diagnose COVID-19" exact="pneumonia" post="from chest CT evaluations has been reported to be"/>
 <result pre="Moreover, the ability of radiologists to diagnose COVID-19 pneumonia from" exact="chest" post="CT evaluations has been reported to be very high"/>
 <result pre="COVID-19 diagnosis. In particular, for early detection and assessment of" exact="disease" post="severity, the high-resolution CT (HRCT) of the chest is"/>
 <result pre="assessment of disease severity, the high-resolution CT (HRCT) of the" exact="chest" post="is considered necessary [130,131]. One study analyzed the consistency"/>
 <result pre="the consistency and diagnostic value of RT-PCR test compared with" exact="chest" post="CT in 1014 patients with suspected SARS-CoV-2 infection. Findings"/>
 <result pre="1014 patients with suspected SARS-CoV-2 infection. Findings indicated that the" exact="chest" post="CT sensitivity in suspected patients was 75% based on"/>
 <result pre="[132]. Moreover, Salehi et al. confirmed the higher sensibility of" exact="pulmonary" post="imaging with respect to RT-PCR for COVID-19 diagnosis and"/>
 <result pre="between specific CT findings with the different stages of the" exact="disease" post="and its severity [116]. The collection of numerous CT"/>
 <result pre="images has opened the possibility to build a database of" exact="pulmonary" post="images from COVID-19 patients. Interestingly, the recent progress in"/>
 <result pre="diagnostic imaging revealed that AI could be used to support" exact="disease" post="diagnosis [133,134]. Ito et al. reviewed the literature on"/>
 <result pre="11 used AI for CT and 4 used AI for" exact="chest" post="radiography. The number of datasets ranged from 106 to"/>
 <result pre="lesions revealed some characteristic CT findings of COVID-19 pneumonia: the" exact="pulmonary" post="ground-glass opacities in a peripheral distribution and the consolidation"/>
 <result pre="findings of COVID-19 pneumonia: the pulmonary ground-glass opacities in a" exact="peripheral" post="distribution and the consolidation referring to an increase in"/>
 <result pre="peripheral distribution and the consolidation referring to an increase in" exact="pulmonary" post="parenchymal density [135,136,137]. However, chest CT manifestations can vary"/>
 <result pre="referring to an increase in pulmonary parenchymal density [135,136,137]. However," exact="chest" post="CT manifestations can vary in different patients and stages"/>
 <result pre="of infection, highlighting certain shortcomings of this approach. Apart from" exact="atypical" post="manifestation that cannot be recognized by radiologists, several lung"/>
 <result pre="be recognized by radiologists, several lung images are common in" exact="viral pneumonia" post="leading to misdiagnosis [138]. Soon after the beginning of"/>
 <result pre="recognized by radiologists, several lung images are common in viral" exact="pneumonia" post="leading to misdiagnosis [138]. Soon after the beginning of"/>
 <result pre="recommended usage of serology to promote the detection of SARS-CoV-2" exact="infections" post="where NP swab specimens were improperly collected, molecular assays"/>
 <result pre="molecular assays were unsatisfactorily carried out and for determining asymptomatic" exact="infections" post="[122]. Based on these data, several companies developed kits"/>
 <result pre="of IgA that seems high in the early stages of" exact="infection" post="(about 4 daysâ€™ post symptom development) [142,143]. Another interesting"/>
 <result pre="many efforts have been intended to develop vaccines against HCoVs" exact="infections" post="in recent years, there is no official and effective"/>
 <result pre="used to cope with COVID-19 epidemic are directed towards specific" exact="viral" post="molecular targets and biologic processes through which the virus"/>
 <result pre="such as inhibitors of SARS-CoV-2 fusion/entry/replication, anti-viral agents against main" exact="viral" post="proteases, regulators of SARS-CoV-2 induced host inflammatory response and"/>
 <result pre="treatment [12,150]. Indeed, this product is mainly used to treat" exact="upper" post="respiratory tract infections such as the flu, swelling and"/>
 <result pre="[12,150]. Indeed, this product is mainly used to treat upper" exact="respiratory" post="tract infections such as the flu, swelling and pain"/>
 <result pre="this product is mainly used to treat upper respiratory tract" exact="infections" post="such as the flu, swelling and pain in the"/>
 <result pre="such as the flu, swelling and pain in the throat," exact="mumps" post="and strep throat [151,152]. Moreover, four COVID-19 cases have"/>
 <result pre="S protein, S1-RBD, expression of virus-like particles (VLP), DNA or" exact="viral" post="vectors [42,154,155,156,157,158]. As outlined above, the S1 includes the"/>
 <result pre="cell membranes promoting the entry and subsequent replication of the" exact="viral" post="RNA into the cytoplasm [158]. The ACE2 receptor, as"/>
 <result pre="(ARBs), such as losartan, valsartan, telmisartan, usually assumed for treating" exact="high blood pressure," post="heart and kidney failure in people with diabetes, have"/>
 <result pre="losartan, valsartan, telmisartan, usually assumed for treating high blood pressure," exact="heart" post="and kidney failure in people with diabetes, have been"/>
 <result pre="telmisartan, usually assumed for treating high blood pressure, heart and" exact="kidney failure" post="in people with diabetes, have been recently proposed as"/>
 <result pre="was shown to be a good target to significantly reduce" exact="pulmonary" post="infection in COVID-19 affected individuals (Figure 8I) [168] Moreover,"/>
 <result pre="shown to be a good target to significantly reduce pulmonary" exact="infection" post="in COVID-19 affected individuals (Figure 8I) [168] Moreover, it"/>
 <result pre="that chloroquine as well as hydroxychloroquine could impair the endosome-mediated" exact="viral" post="entry or later stages of viral replication [173]. Combination"/>
 <result pre="could impair the endosome-mediated viral entry or later stages of" exact="viral" post="replication [173]. Combination of hydroxychloroquine and azithromycin has also"/>
 <result pre="a valid approach since it showed more rapid resolution of" exact="infection" post="than hydroxychloroquine alone [174]; however, the combined use of"/>
 <result pre="To date, several attempts have also been made in targeting" exact="viral" post="main enzymes; in fact, many inhibitory drugs targeting the"/>
 <result pre="detected by high-throughput screening, showed reasonable binding conformations with the" exact="viral" post="main protease [176]. Moreover, a recent study by performing"/>
 <result pre="only for their effective and synergic inhibitory activities against two" exact="viral" post="enzymes, but also for their minimized possibilities to develop"/>
 <result pre="organ infected by SARS-CoV-2 [180]. 6.4. Modulators of SARS-CoV-2 Induced" exact="Inflammatory" post="Response In addition to antiviral therapy, a new treatment"/>
 <result pre="involved in inflammatory cytokines-receptors interactions, their correlation in health and" exact="disease" post="and drugs in use that can activate or block"/>
 <result pre="cytokine storm could be linked to the severity of the" exact="disease" post="[113]. Corticosteroids are among the most commonly used drugs"/>
 <result pre="among the most commonly used drugs for immunomodulatory therapy of" exact="infectious diseases." post="However, the use of corticosteroids in the treatment of"/>
 <result pre="of COVID-19 can cause host immune suppression and delay of" exact="viral" post="clearance. A recent study on 201 patients with ARDS"/>
 <result pre="0.20â€&quot;0.72). These findings indicate that using corticosteroids does not influence" exact="viral" post="clearance time, length of hospital stays or duration of"/>
 <result pre="has been indicated for specific reasons such as exacerbation of" exact="asthma" post="or chronic obstructive pulmonary disease (COPD), septic shock or"/>
 <result pre="been indicated for specific reasons such as exacerbation of asthma" exact="or chronic" post="obstructive pulmonary disease (COPD), septic shock or severe acute"/>
 <result pre="indicated for specific reasons such as exacerbation of asthma or" exact="chronic" post="obstructive pulmonary disease (COPD), septic shock or severe acute"/>
 <result pre="specific reasons such as exacerbation of asthma or chronic obstructive" exact="pulmonary" post="disease (COPD), septic shock or severe acute respiratory distress"/>
 <result pre="reasons such as exacerbation of asthma or chronic obstructive pulmonary" exact="disease" post="(COPD), septic shock or severe acute respiratory distress syndrome"/>
 <result pre="as exacerbation of asthma or chronic obstructive pulmonary disease (COPD)," exact="septic shock" post="or severe acute respiratory distress syndrome (ARDS). Further studies"/>
 <result pre="or chronic obstructive pulmonary disease (COPD), septic shock or severe" exact="acute" post="respiratory distress syndrome (ARDS). Further studies are required to"/>
 <result pre="chronic obstructive pulmonary disease (COPD), septic shock or severe acute" exact="respiratory" post="distress syndrome (ARDS). Further studies are required to find"/>
 <result pre="pulmonary disease (COPD), septic shock or severe acute respiratory distress" exact="syndrome" post="(ARDS). Further studies are required to find out how"/>
 <result pre="on the benefits of corticosteroid treatment in SARS-CoV or MERS" exact="infection" post="[183]. Apart from corticosteroids, IL-6 pathway inhibitors such as"/>
 <result pre="recombinant, humanized monoclonal antibody commonly used for treating patients with" exact="rheumatoid arthritis," post="lupus and psoriasis that binds to IL-6 receptors blocking"/>
 <result pre="monoclonal antibody commonly used for treating patients with rheumatoid arthritis," exact="lupus" post="and psoriasis that binds to IL-6 receptors blocking FcR"/>
 <result pre="commonly used for treating patients with rheumatoid arthritis, lupus and" exact="psoriasis" post="that binds to IL-6 receptors blocking FcR activation; in"/>
 <result pre="proposed as a principal treatment [190,191], for patients in rapid" exact="disease" post="progression, severe or critical conditions (Figure 8VI). In a"/>
 <result pre="(200 mL) of convalescent plasma (CP) collected from 10 severe" exact="adult" post="cases has been reported to be tolerated; thus, increasing"/>
 <result pre="or maintaining high level of neutralizing antibodies broke down the" exact="viral" post="load in seven days, improve clinical symptoms and paraclinical"/>
 <result pre="better understand if these therapies could be effective in treating" exact="respiratory" post="virus-induced complications. MSCs have been largely employed in basic"/>
 <result pre="extensively documented especially in immune-mediated inflammatory disorders, such as graft-versus-host" exact="disease" post="(GVHD) [199] and systemic lupus erythematosus (SLE) [200]. MSCs"/>
 <result pre="immune-mediated inflammatory disorders, such as graft-versus-host disease (GVHD) [199] and" exact="systemic" post="lupus erythematosus (SLE) [200]. MSCs immunomodulatory and differentiation abilities"/>
 <result pre="inflammatory disorders, such as graft-versus-host disease (GVHD) [199] and systemic" exact="lupus erythematosus" post="(SLE) [200]. MSCs immunomodulatory and differentiation abilities [201] as"/>
 <result pre="priming the immune response during infections. Two clinical investigations of" exact="systemic" post="MSC administration in patients with either COVID-19 or avian"/>
 <result pre="of systemic MSC administration in patients with either COVID-19 or" exact="avian influenza" post="A (H7N9) have been recently published [205,206]. The first"/>
 <result pre="aimed at exploring MSCs therapeutic potentiality in patients with COVID-19" exact="pneumonia" post="and conducted at the Youâ€™an Hospital in Beijing, China,"/>
 <result pre="for 14 days after MSC injection. A significant improvement of" exact="pulmonary" post="function and symptoms were observed two days after MSC"/>
 <result pre="two days after MSC transplantation characterized by an increase of" exact="peripheral" post="lymphocytes and of the anti-inflammatory IL-10 levels and a"/>
 <result pre="importantly, because these cells do not express ACE2 and TMPRSS2" exact="viral" post="receptors are insusceptible of SARS-CoV-2 infection. These observations are"/>
 <result pre="of the immune system and promotes endogenous repair by preventing" exact="pulmonary" post="fibrosis and improving both pulmonary microenvironment and lung function"/>
 <result pre="promotes endogenous repair by preventing pulmonary fibrosis and improving both" exact="pulmonary" post="microenvironment and lung function [205]. 6.7. Vaccines More than"/>
 <result pre="including inactivated, recombinant subunits, nucleic-acid-based, adenoviral vector, and recombinant influenza" exact="viral" post="vector vaccines [208]. Moreover, taking into consideration the strong"/>
 <result pre="be a valuable alternative therapeutic strategy [209]. The Coalition for" exact="Epidemic" post="Preparedness Innovations (CEPI) recently announced that three programs aimed"/>
 <result pre="components to a defined skin microenvironment improves safety by reducing" exact="systemic" post="exposure, allowing to reach high vaccine concentrations with a"/>
 <result pre="strategy seems to be a promising immunization approach against coronavirus" exact="infection" post="including SARS, MERS and other emerging infectious diseases. On"/>
 <result pre="approach against coronavirus infection including SARS, MERS and other emerging" exact="infectious diseases." post="On April 24, the Oxford ChAdOx1 nCov-19 vaccine was"/>
 <result pre="ChAdOx1 in the past to dispense vaccines against Ebola, Chikungunya," exact="Rift Valley fever" post="and, above all, MERS. ChAdOx1, a chimpanzee-derived adenovirus vector,"/>
 <result pre="30 April 2020). Since ChAdOx technology is already available and" exact="formerly" post="tested in humans for other vaccines, Phase III will"/>
 <result pre="to ensure that these subjects actually become immune to the" exact="disease" post="up to three years. If trials succeed, Oxford researchers"/>
 <result pre="three years. If trials succeed, Oxford researchers have proposed to" exact="complete" post="testing throughout ring vaccination, namely delivering vaccine to members"/>
 <result pre="antiviral drugs and vaccines towards existing and potential future coronavirus" exact="infections" post="to prevent another highly pathogenic virus epidemic. Moreover, continuous"/>
 <result pre="pandemic and provide a reference for future studies to combat" exact="disease" post="progression. Despite SARS-CoV-2 rapid transmission, the scale up country"/>
 <result pre="ongoing and expanding, further studies on all aspects of the" exact="disease" post="are needed to better understand the infection, beneficial treatments"/>
 <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
 <result pre="2019 novel coronavirus (2019-nCoV); 3-chymotrypsin-like protease (3CLpro); 3C-like protease (3CL);" exact="Acute respiratory distress syndrome" post="(ARDS); adeno-associated virus (AAV); angiotensin receptor blockers (ARBs); angiotensin-converting"/>
 <result pre="novel coronavirus (2019-nCoV); 3-chymotrypsin-like protease (3CLpro); 3C-like protease (3CL); Acute" exact="respiratory" post="distress syndrome (ARDS); adeno-associated virus (AAV); angiotensin receptor blockers"/>
 <result pre="(2019-nCoV); 3-chymotrypsin-like protease (3CLpro); 3C-like protease (3CL); Acute respiratory distress" exact="syndrome" post="(ARDS); adeno-associated virus (AAV); angiotensin receptor blockers (ARBs); angiotensin-converting"/>
 <result pre="(ACE2); AP-2-associated protein kinase 1 (AAK1); artificial intelligence (AI); avian" exact="infectious" post="bronchitis virus (IBV); basic reproduction number (R0); blood oxygen"/>
 <result pre="AP-2-associated protein kinase 1 (AAK1); artificial intelligence (AI); avian infectious" exact="bronchitis" post="virus (IBV); basic reproduction number (R0); blood oxygen saturation"/>
 <result pre="(R0); blood oxygen saturation (SpO2); bronchoalveolar lavage (BAL); centers for" exact="disease" post="control and prevention (CDC); Chinese Center for Disease Control"/>
 <result pre="centers for disease control and prevention (CDC); Chinese Center for" exact="Disease" post="Control and Prevention (China CDC); chronic obstructive pulmonary disease"/>
 <result pre="(CDC); Chinese Center for Disease Control and Prevention (China CDC);" exact="chronic" post="obstructive pulmonary disease (COPD); Coalition for Epidemic Preparedness Innovations"/>
 <result pre="Center for Disease Control and Prevention (China CDC); chronic obstructive" exact="pulmonary" post="disease (COPD); Coalition for Epidemic Preparedness Innovations (CEPI); computed"/>
 <result pre="for Disease Control and Prevention (China CDC); chronic obstructive pulmonary" exact="disease" post="(COPD); Coalition for Epidemic Preparedness Innovations (CEPI); computed tomography"/>
 <result pre="Prevention (China CDC); chronic obstructive pulmonary disease (COPD); Coalition for" exact="Epidemic" post="Preparedness Innovations (CEPI); computed tomography (CT); computer-aided design (CAD);"/>
 <result pre="Center for Medium-Range Weather Forecasts (ECMWF); European cities (ECs); feline" exact="infectious" post="peritonitis (FIP); graft versus-host disease (GVHD); hemagglutinin-esterase glycoprotein (HE);"/>
 <result pre="for Medium-Range Weather Forecasts (ECMWF); European cities (ECs); feline infectious" exact="peritonitis" post="(FIP); graft versus-host disease (GVHD); hemagglutinin-esterase glycoprotein (HE); heptad"/>
 <result pre="(ECMWF); European cities (ECs); feline infectious peritonitis (FIP); graft versus-host" exact="disease" post="(GVHD); hemagglutinin-esterase glycoprotein (HE); heptad repeat 1 (HR1) and"/>
 <result pre="(M); mesenchymal stromal cells (MSCs); microneedle arrays (MNAs); Middle East" exact="Respiratory" post="syndrome coronavirus (MERS-CoV); monoclonal antibodies (mAbs); naso-pharyngeal (NP); National"/>
 <result pre="mesenchymal stromal cells (MSCs); microneedle arrays (MNAs); Middle East Respiratory" exact="syndrome" post="coronavirus (MERS-CoV); monoclonal antibodies (mAbs); naso-pharyngeal (NP); National Health"/>
 <result pre="(N); open reading frames (ORFs); oro-pharyngeal (OP); papain-like protease (PLpro);" exact="partial" post="pressure of arterial oxygen to fraction of inspired oxygen"/>
 <result pre="molecules (PAMPs); Pittsburgh coronavirus vaccine (PittCoVacc); polypeptides (pps); porcine epidemic" exact="diarrhea" post="virus (PEDV); real time quantitative polymerase chain reaction (RT-qPCR);"/>
 <result pre="(RTC); RNA-dependent RNA polymerase (RdRp); RNase P gene (RP); severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV); single-stranded positive-sense RNA (+ssRNA); Southern"/>
 <result pre="RNA-dependent RNA polymerase (RdRp); RNase P gene (RP); severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV); single-stranded positive-sense RNA (+ssRNA); Southern Hemisphere"/>
 <result pre="RNA polymerase (RdRp); RNase P gene (RP); severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV); single-stranded positive-sense RNA (+ssRNA); Southern Hemisphere (SH);"/>
 <result pre="Southern Hemisphere (SH); spike glycoprotein (S); subgenomic RNAs (sgRNAs); swine" exact="acute" post="diarrhea syndrome coronavirus (SADS-CoV); swine enteric Alphacoronaviruses (SeACoVs); systemic"/>
 <result pre="Hemisphere (SH); spike glycoprotein (S); subgenomic RNAs (sgRNAs); swine acute" exact="diarrhea" post="syndrome coronavirus (SADS-CoV); swine enteric Alphacoronaviruses (SeACoVs); systemic lupus"/>
 <result pre="(SH); spike glycoprotein (S); subgenomic RNAs (sgRNAs); swine acute diarrhea" exact="syndrome" post="coronavirus (SADS-CoV); swine enteric Alphacoronaviruses (SeACoVs); systemic lupus erythematosus"/>
 <result pre="swine acute diarrhea syndrome coronavirus (SADS-CoV); swine enteric Alphacoronaviruses (SeACoVs);" exact="systemic" post="lupus erythematosus (SLE); transmissible gastroenteritis virus (TGEV); virus-like particles"/>
 <result pre="acute diarrhea syndrome coronavirus (SADS-CoV); swine enteric Alphacoronaviruses (SeACoVs); systemic" exact="lupus erythematosus" post="(SLE); transmissible gastroenteritis virus (TGEV); virus-like particles (VLP); WHOâ€™s"/>
 <result pre="(SADS-CoV); swine enteric Alphacoronaviruses (SeACoVs); systemic lupus erythematosus (SLE); transmissible" exact="gastroenteritis" post="virus (TGEV); virus-like particles (VLP); WHOâ€™s International Clinical Trials"/>
 <result pre="Health Organization (WHO). References References 1.ChanJ.F.LauS.K.WooP.C.The emerging novel Middle East" exact="respiratory" post="syndrome coronavirus: The â€œknownsâ€� and â€œunknownsâ€�J. Formos. Med. Assoc.201311237238110.1016/j.jfma.2013.05.01023883791"/>
 <result pre="Organization (WHO). References References 1.ChanJ.F.LauS.K.WooP.C.The emerging novel Middle East respiratory" exact="syndrome" post="coronavirus: The â€œknownsâ€� and â€œunknownsâ€�J. Formos. Med. Assoc.201311237238110.1016/j.jfma.2013.05.01023883791 2.ZumlaA.ChanJ.F.AzharE.I.HuiD.S.YuenK.Y.Coronavirusesâ€&quot;Drug"/>
 <result pre="8.ScottF.W.Evaluation of risks and benefits associated with vaccination against coronavirus" exact="infections" post="in catsAdv. Vet. Med.19994134735810.1016/s0065-3519(99)80026-39890027 9.DrostenC.GÃ¼ntherS.PreiserW.van der WerfS.BrodtH.R.BeckerS.RabenauH.PanningM.KolesnikovaL.FouchierR.A.Identification of a"/>
 <result pre="der WerfS.BrodtH.R.BeckerS.RabenauH.PanningM.KolesnikovaL.FouchierR.A.Identification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndromeN. Engl. J. Med.20033481967197610.1056/NEJMoa03074712690091 10.ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a"/>
 <result pre="WerfS.BrodtH.R.BeckerS.RabenauH.PanningM.KolesnikovaL.FouchierR.A.Identification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndromeN. Engl. J. Med.20033481967197610.1056/NEJMoa03074712690091 10.ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel"/>
 <result pre="10.ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN. Engl. J. Med.20123671814182010.1056/NEJMoa121172123075143 11.ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.et al.China Novel"/>
 <result pre="Investigating and Research Team. A Novel Coronavirus from Patients with" exact="Pneumonia" post="in China, 2019N. Engl. J. Med.20203872773310.1056/NEJMoa200101731978945 12.LuH.StrattonC.W.TangY.W.Outbreak of pneumonia"/>
 <result pre="with Pneumonia in China, 2019N. Engl. J. Med.20203872773310.1056/NEJMoa200101731978945 12.LuH.StrattonC.W.TangY.W.Outbreak of" exact="pneumonia" post="of unknown etiology in Wuhan, China: The mystery and"/>
 <result pre="Group of the International Committee on Taxonomy of VirusesThe species" exact="Severe" post="acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it"/>
 <result pre="of the International Committee on Taxonomy of VirusesThe species Severe" exact="acute" post="respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2Nat."/>
 <result pre="the International Committee on Taxonomy of VirusesThe species Severe acute" exact="respiratory" post="syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2Nat. Microbiol.2020553654410.1038/s41564-020-0695-z32123347"/>
 <result pre="evolution of pathogenic coronavirusesNat. Rev. Microbiol.20191718119210.1038/s41579-018-0118-930531947 18.DrexlerJ.F.Gloza-RauschF.GlendeJ.CormanV.M.MuthD.GoettscheM.SeebensA.NiedrigM.PfefferleS.YordanovS.et al.Genomic Characterization of" exact="Severe" post="Acute Respiratory Syndrome-Related Coronavirus in European Bats and Classification"/>
 <result pre="of pathogenic coronavirusesNat. Rev. Microbiol.20191718119210.1038/s41579-018-0118-930531947 18.DrexlerJ.F.Gloza-RauschF.GlendeJ.CormanV.M.MuthD.GoettscheM.SeebensA.NiedrigM.PfefferleS.YordanovS.et al.Genomic Characterization of Severe" exact="Acute" post="Respiratory Syndrome-Related Coronavirus in European Bats and Classification of"/>
 <result pre="pathogenic coronavirusesNat. Rev. Microbiol.20191718119210.1038/s41579-018-0118-930531947 18.DrexlerJ.F.Gloza-RauschF.GlendeJ.CormanV.M.MuthD.GoettscheM.SeebensA.NiedrigM.PfefferleS.YordanovS.et al.Genomic Characterization of Severe Acute" exact="Respiratory" post="Syndrome-Related Coronavirus in European Bats and Classification of Coronaviruses"/>
 <result pre="Coronavirus in European Bats and Classification of Coronaviruses Based on" exact="Partial" post="RNA-Dependent RNA Polymerase Gene SequencesJ. Virol.201084113361134910.1128/JVI.00650-1020686038 19.LuR.ZhaoX.LiJ.NiuP.YangB.WuH.WangW.SongH.HuangB.ZhuN.et al.Genomic characterisation"/>
 <result pre="receptor bindingLancet202039556557410.1016/S0140-6736(20)30251-832007145 20.PeirisJ.S.LaiS.T.PoonL.L.GuanY.YamL.Y.LimW.NichollsJ.YeeW.K.YanW.W.CheungM.T.et al.Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndromeLancet20033611319132510.1016/S0140-6736(03)13077-212711465 21.YinY.WunderinkR.G.MERS, SARS and other coronaviruses as causes"/>
 <result pre="bindingLancet202039556557410.1016/S0140-6736(20)30251-832007145 20.PeirisJ.S.LaiS.T.PoonL.L.GuanY.YamL.Y.LimW.NichollsJ.YeeW.K.YanW.W.CheungM.T.et al.Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndromeLancet20033611319132510.1016/S0140-6736(03)13077-212711465 21.YinY.WunderinkR.G.MERS, SARS and other coronaviruses as causes of"/>
 <result pre="and other coronaviruses as causes of pneumoniaRespirology20182313013710.1111/resp.1319629052924 22.ImaiN.DorigattiI.CoriA.DonnellyC.RileyS.FergusonN.M.Estimating the potential" exact="total" post="number of novel Coronavirus cases in Wuhan City, ChinaImp."/>
 <result pre="25.SuS.WongG.ShiW.LiuJ.LaiA.ZhouJ.LiuW.BiY.GaoG.F.Epidemiology, Genetic Recombination, and Pathogenesis of CoronavirusesTrends Microbiol.20162449050210.1016/j.tim.2016.03.00327012512 26.MiÅ‚ekJ.Blicharz-DomaÅ&quot;skaK.Coronaviruses in" exact="Avian" post="Speciesâ€&quot;Review with Focus on Epidemiology and Diagnosis in Wild"/>
 <result pre="Origin of SARS-CoV-2 Associated with the COVID-19 OutbreakCurr. Biol.20203013461351.e210.1016/j.cub.2020.03.02232197085 28.HeF.DengY.LiW.Coronavirus" exact="disease" post="2019: What we know?J. Med. Virol.20209271972510.1002/jmv.2576632170865 29.SchlottauK.RissmannM.GraafA.SchÃ¶nJ.SehlJ.WylezichC.HÃ¶perD.MettenleiterT.C.Balkema-BuschmannA.HarderT.et al.SARS-CoV-2 in"/>
 <result pre="der HoekL.Identification of new human coronavirusesExpert Rev. Anti-Infect. Ther.2007524525310.1586/14787210.5.2.24517402839 33.RomanoM.RuggieroA.SquegliaF.MagaG.BerisioR.A" exact="Structural" post="View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 38.NalB.ChanC.KienF.SiuL.TseJ.ChuK.KamJ.StaropoliI.Crescenzo-ChaigneB.EscriouN.et al.Differential maturation and"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 38.NalB.ChanC.KienF.SiuL.TseJ.ChuK.KamJ.StaropoliI.Crescenzo-ChaigneB.EscriouN.et al.Differential maturation and"/>
 <result pre="Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 38.NalB.ChanC.KienF.SiuL.TseJ.ChuK.KamJ.StaropoliI.Crescenzo-ChaigneB.EscriouN.et al.Differential maturation and subcellular localization of severe" exact="acute" post="respiratory syndrome coronavirus surface proteins S, M and EJ."/>
 <result pre="Infect.2020922123610.1080/22221751.2020.171990231987001 38.NalB.ChanC.KienF.SiuL.TseJ.ChuK.KamJ.StaropoliI.Crescenzo-ChaigneB.EscriouN.et al.Differential maturation and subcellular localization of severe acute" exact="respiratory" post="syndrome coronavirus surface proteins S, M and EJ. Gen."/>
 <result pre="38.NalB.ChanC.KienF.SiuL.TseJ.ChuK.KamJ.StaropoliI.Crescenzo-ChaigneB.EscriouN.et al.Differential maturation and subcellular localization of severe acute respiratory" exact="syndrome" post="coronavirus surface proteins S, M and EJ. Gen. Virol.2005861423143410.1099/vir.0.80671-015831954"/>
 <result pre="al.The M, E, and N structural proteins of the severe" exact="acute" post="respiratory syndrome coronavirus are required for efficient assembly, trafficking,"/>
 <result pre="M, E, and N structural proteins of the severe acute" exact="respiratory" post="syndrome coronavirus are required for efficient assembly, trafficking, and"/>
 <result pre="E, and N structural proteins of the severe acute respiratory" exact="syndrome" post="coronavirus are required for efficient assembly, trafficking, and release"/>
 <result pre="coronavirusScience20033001399140410.1126/science.108595312730501 44.RotaP.A.ObersteM.S.MonroeS.S.NixW.A.CampagnoliR.IcenogleJ.P.PeÃ±arandaS.BankampB.MaherK.ChenM.H.et al.Characterization of a novel coronavirus associated with severe" exact="acute" post="respiratory syndromeScience20033001394139910.1126/science.108595212730500 45.SnijderE.J.BredenbeekP.J.DobbeJ.C.ThielV.ZiebuhrJ.PoonL.L.GuanY.RozanovM.SpaanW.J.GorbalenyaA.E.Unique and conserved features of genome and"/>
 <result pre="44.RotaP.A.ObersteM.S.MonroeS.S.NixW.A.CampagnoliR.IcenogleJ.P.PeÃ±arandaS.BankampB.MaherK.ChenM.H.et al.Characterization of a novel coronavirus associated with severe acute" exact="respiratory" post="syndromeScience20033001394139910.1126/science.108595212730500 45.SnijderE.J.BredenbeekP.J.DobbeJ.C.ThielV.ZiebuhrJ.PoonL.L.GuanY.RozanovM.SpaanW.J.GorbalenyaA.E.Unique and conserved features of genome and proteome"/>
 <result pre="bovine coronavirusJ. Virol.1999733737374310.1128/JVI.73.5.3737-3743.199910196267 48.WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe" exact="acute" post="respiratory syndrome coronavirusMicrobiol. Mol. Biol. Rev.20056963566410.1128/MMBR.69.4.635-664.200516339739 49.WuA.PengY.HuangB.DingX.WangX.NiuP.MengJ.ZhuZ.ZhangZ.WangJ.et al.Genome Composition"/>
 <result pre="coronavirusJ. Virol.1999733737374310.1128/JVI.73.5.3737-3743.199910196267 48.WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe acute" exact="respiratory" post="syndrome coronavirusMicrobiol. Mol. Biol. Rev.20056963566410.1128/MMBR.69.4.635-664.200516339739 49.WuA.PengY.HuangB.DingX.WangX.NiuP.MengJ.ZhuZ.ZhangZ.WangJ.et al.Genome Composition and"/>
 <result pre="Virol.1999733737374310.1128/JVI.73.5.3737-3743.199910196267 48.WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe acute respiratory" exact="syndrome" post="coronavirusMicrobiol. Mol. Biol. Rev.20056963566410.1128/MMBR.69.4.635-664.200516339739 49.WuA.PengY.HuangB.DingX.WangX.NiuP.MengJ.ZhuZ.ZhangZ.WangJ.et al.Genome Composition and Divergence"/>
 <result pre="the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long" exact="Structural" post="Studies of SARS CoronavirusJ. Virol.20209410.1128/JVI.00127-2031996437 52.WrappD.WangN.CorbettK.S.GoldsmithJ.A.HsiehC.L.AbionaO.GrahamB.S.McLellanJ.S.Cryo-EM structure of the"/>
 <result pre="and Antigenicity of the SARS-CoV-2 Spike GlycoproteinCell2020181281292.e610.1016/j.cell.2020.02.05832155444 55.SimmonsG.ReevesJ.D.RennekampA.J.AmbergS.M.PieferA.J.BatesP.Characterization of severe" exact="acute" post="respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entryProc. Natl."/>
 <result pre="Antigenicity of the SARS-CoV-2 Spike GlycoproteinCell2020181281292.e610.1016/j.cell.2020.02.05832155444 55.SimmonsG.ReevesJ.D.RennekampA.J.AmbergS.M.PieferA.J.BatesP.Characterization of severe acute" exact="respiratory" post="syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entryProc. Natl. Acad."/>
 <result pre="55.SimmonsG.ReevesJ.D.RennekampA.J.AmbergS.M.PieferA.J.BatesP.Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated" exact="viral" post="entryProc. Natl. Acad. Sci. USA20041014240424510.1073/pnas.030644610115010527 56.HeY.LiJ.DuL.YanX.HuG.ZhouY.JiangS.Identification and characterization of"/>
 <result pre="SARS-CoV vaccineVaccine2006245498550810.1016/j.vaccine.2006.04.05416725238 57.WuZ.McGooganJ.M.Characteristics of and Important Lessons from the Coronavirus" exact="Disease" post="2019 (COVID-19) Outbreak in China: Summary of a Report"/>
 <result pre="a Report of 72,314 Cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA20203231239124210.1001/jama.2020.2648 58.RajV.S.MouH.SmitsS.L.DekkersD.H.MÃ¼llerM.A.DijkmanR.MuthD.DemmersJ.A.ZakiA.FouchierR.A.et al.Dipeptidyl peptidase 4 is a"/>
 <result pre="from human to pigEmerg. Infect. Dis.20051144644810.3201/eid1103.04082415757562 65.Vergara-AlertJ.van den BrandJ.M.WidagdoW.MuÃ±ozM.RajS.SchipperD.SolanesD.CordÃ³nI.BensaidA.HaagmansB.L.et al.Livestock" exact="Susceptibility to" post="Infection with Middle East Respiratory Syndrome CoronavirusEmerg. Infect. Dis.20172323224010.3201/eid2302.16123927901465"/>
 <result pre="to pigEmerg. Infect. Dis.20051144644810.3201/eid1103.04082415757562 65.Vergara-AlertJ.van den BrandJ.M.WidagdoW.MuÃ±ozM.RajS.SchipperD.SolanesD.CordÃ³nI.BensaidA.HaagmansB.L.et al.Livestock Susceptibility to" exact="Infection" post="with Middle East Respiratory Syndrome CoronavirusEmerg. Infect. Dis.20172323224010.3201/eid2302.16123927901465 66.HuangC.LiuW.J.XuW.JinT.ZhaoY.SongJ.ShiY.JiW.JiaH.ZhouY.et"/>
 <result pre="65.Vergara-AlertJ.van den BrandJ.M.WidagdoW.MuÃ±ozM.RajS.SchipperD.SolanesD.CordÃ³nI.BensaidA.HaagmansB.L.et al.Livestock Susceptibility to Infection with Middle East" exact="Respiratory" post="Syndrome CoronavirusEmerg. Infect. Dis.20172323224010.3201/eid2302.16123927901465 66.HuangC.LiuW.J.XuW.JinT.ZhaoY.SongJ.ShiY.JiW.JiaH.ZhouY.et al.A Bat-Derived Putative Cross-Family"/>
 <result pre="den BrandJ.M.WidagdoW.MuÃ±ozM.RajS.SchipperD.SolanesD.CordÃ³nI.BensaidA.HaagmansB.L.et al.Livestock Susceptibility to Infection with Middle East Respiratory" exact="Syndrome" post="CoronavirusEmerg. Infect. Dis.20172323224010.3201/eid2302.16123927901465 66.HuangC.LiuW.J.XuW.JinT.ZhaoY.SongJ.ShiY.JiW.JiaH.ZhouY.et al.A Bat-Derived Putative Cross-Family Recombinant"/>
 <result pre="Dis.20172323224010.3201/eid2302.16123927901465 66.HuangC.LiuW.J.XuW.JinT.ZhaoY.SongJ.ShiY.JiW.JiaH.ZhouY.et al.A Bat-Derived Putative Cross-Family Recombinant Coronavirus with a" exact="Reovirus" post="GenePLoS Pathog.201612e100588310.1371/journal.ppat.100588327676249 67.ForsterP.ForsterL.RenfrewC.ForsterM.Phylogenetic network analysis of SARS-CoV-2 genomesProc. Natl."/>
 <result pre="of SARS-CoV-2 genomesProc. Natl. Acad. Sci. USA20201179241924310.1073/pnas.200499911732269081 68.LiW.ZhangC.SuiJ.KuhnJ.H.MooreM.J.LuoS.WongS.K.HuangI.C.XuK.VasilievaN.et al.Receptor and" exact="viral" post="determinants of SARS-coronavirus adaptation to human ACE2EMBO J.2005241634164310.1038/sj.emboj.760064015791205 69.JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2"/>
 <result pre="adaptation to human ACE2EMBO J.2005241634164310.1038/sj.emboj.760064015791205 69.JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2 receptor expression and severe" exact="acute" post="respiratory syndrome coronavirus infection depend on differentiation of human"/>
 <result pre="to human ACE2EMBO J.2005241634164310.1038/sj.emboj.760064015791205 69.JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2 receptor expression and severe acute" exact="respiratory" post="syndrome coronavirus infection depend on differentiation of human airway"/>
 <result pre="human ACE2EMBO J.2005241634164310.1038/sj.emboj.760064015791205 69.JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2 receptor expression and severe acute respiratory" exact="syndrome" post="coronavirus infection depend on differentiation of human airway epitheliaJ."/>
 <result pre="J.2005241634164310.1038/sj.emboj.760064015791205 69.JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epitheliaJ. Virol.200579146141462110.1128/JVI.79.23.14614-14621.200516282461 70.OrtegaJ.T.SerranoM.L.PujolF.H.RangelH.R.Role"/>
 <result pre="analysisEXCLI J.20201910.17179/excli2020-1167 71.ShangJ.YeG.ShiK.WanY.LuoC.AiharaH.GengQ.AuerbachA.LiF.Structural basis of receptor recognition by SARS-CoV-2Nature202058122122410.1038/s41586-020-2179-y32225175 72.CiagliaE.VecchioneC.PucaA.A.COVID-19" exact="Infection" post="and Circulating ACE2 Levels: Protective Role in Women and"/>
 <result pre="of big numbers in the time of COVID-19medRxiv202010.2139/ssrn.3590183 74.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2" exact="Viral" post="Load in Upper Respiratory Specimens of Infected PatientsN. Engl."/>
 <result pre="the time of COVID-19medRxiv202010.2139/ssrn.3590183 74.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2 Viral Load in Upper" exact="Respiratory" post="Specimens of Infected PatientsN. Engl. J. Med.20203821177117910.1056/NEJMc200173732074444 75.PetrosilloN.ViceconteG.ErgonulO.IppolitoG.PetersenE.COVID-19, SARS"/>
 <result pre="July 2020) 77.HanY.YangH.The transmission and diagnosis of 2019 novel coronavirus" exact="infection" post="disease (COVID-19): A Chinese perspectiveJ. Med. Virol.20201010.1002/jmv.25749 78.RothanH.A.ByrareddyS.N.The epidemiology"/>
 <result pre="2020) 77.HanY.YangH.The transmission and diagnosis of 2019 novel coronavirus infection" exact="disease" post="(COVID-19): A Chinese perspectiveJ. Med. Virol.20201010.1002/jmv.25749 78.RothanH.A.ByrareddyS.N.The epidemiology and"/>
 <result pre="Chinese perspectiveJ. Med. Virol.20201010.1002/jmv.25749 78.RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ. Autoimmun.202010910243310.1016/j.jaut.2020.10243332113704 79.KampfG.TodtD.PfaenderS.SteinmannE.Persistence of coronaviruses on inanimate surfaces"/>
 <result pre="transmission of SARS-CoV-2 possible?Lancet Gastroenterol. Hepatol.2020533533710.1016/S2468-1253(20)30048-032087098 81.LuC.W.LiuX.F.JiaZ.F.2019-nCoV transmission through the" exact="ocular" post="surface must not be ignoredLancet2020395e3910.1016/S0140-6736(20)30313-532035510 82.collab: Special Expert Group"/>
 <result pre="be ignoredLancet2020395e3910.1016/S0140-6736(20)30313-532035510 82.collab: Special Expert Group for Control of the" exact="Epidemic" post="of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine"/>
 <result pre="Expert Group for Control of the Epidemic of Novel Coronavirus" exact="Pneumonia" post="of the Chinese Preventive Medicine AssociationAn update on the"/>
 <result pre="Medicine AssociationAn update on the epidemiological characteristics of novel coronavirus" exact="pneumonia" post="(COVID-19)Zhonghua Liu Xing Bing Xue Za Zhi20204113914410.3760/cma.j.issn.0254-6450.2020.02.00232057211 83.ChenH.GuoJ.WangC.LuoF.YuX.ZhangW.LiJ.ZhaoD.XuD.GongQ.et al.Clinical"/>
 <result pre="83.ChenH.GuoJ.WangC.LuoF.YuX.ZhangW.LiJ.ZhaoD.XuD.GongQ.et al.Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: A retrospective review of medical"/>
 <result pre="pregnant women: A retrospective review of medical recordsLancet202039580981510.1016/S0140-6736(20)30360-332151335 84.WeiM.YuanJ.LiuY.FuT.YuX.ZhangZ.J.Novel Coronavirus" exact="Infection" post="in Hospitalized Infants Under 1 Year of Age in"/>
 <result pre="89.collab: National Health Commission of the Peopleâ€™s Republic of ChinaPneumonia" exact="Epidemic" post="Situation of New Coronavirus Infection on 23 January 2020Available"/>
 <result pre="the Peopleâ€™s Republic of ChinaPneumonia Epidemic Situation of New Coronavirus" exact="Infection" post="on 23 January 2020Available online: http://www.nhc.gov.cn/yjb/s3578/202001/5d19a4f6d3154b9fae328918ed2e3c8a.shtml(accessed on 23 January"/>
 <result pre="for international spread via commercial air travelJ. Travel Med.20202710.1093/jtm/taaa008 91.McCrearyE.K.PogueJ.M.Coronavirus" exact="Disease" post="2019 Treatment: A Review of Early and Emerging OptionsOpen"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: A descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 93.ChengZ.J.ShanJ.2019 Novel coronavirus:"/>
 <result pre="and what we knowInfection20204815516310.1007/s15010-020-01401-y32072569 94.LinQ.ChiuA.P.ZhaoS.HeD.Modeling the spread of Middle East" exact="respiratory" post="syndrome coronavirus in Saudi ArabiaStat. Methods Med. Res.2018271968197810.1177/096228021774644229846148 95.LipsitchM.CohenT.CooperB.RobinsJ.M.MaS.JamesL.GopalakrishnaG.ChewS.K.TanC.C.SamoreM.H.et"/>
 <result pre="what we knowInfection20204815516310.1007/s15010-020-01401-y32072569 94.LinQ.ChiuA.P.ZhaoS.HeD.Modeling the spread of Middle East respiratory" exact="syndrome" post="coronavirus in Saudi ArabiaStat. Methods Med. Res.2018271968197810.1177/096228021774644229846148 95.LipsitchM.CohenT.CooperB.RobinsJ.M.MaS.JamesL.GopalakrishnaG.ChewS.K.TanC.C.SamoreM.H.et al.Transmission"/>
 <result pre="Methods Med. Res.2018271968197810.1177/096228021774644229846148 95.LipsitchM.CohenT.CooperB.RobinsJ.M.MaS.JamesL.GopalakrishnaG.ChewS.K.TanC.C.SamoreM.H.et al.Transmission dynamics and control of severe" exact="acute" post="respiratory syndromeScience20033001966197010.1126/science.108661612766207 96.MoriyamaM.HugentoblerW.J.IwasakiA.Seasonality of Respiratory Viral InfectionsAnnu. Rev. Virol.20201010.1146/annurev-virology-012420-02244532196426"/>
 <result pre="Med. Res.2018271968197810.1177/096228021774644229846148 95.LipsitchM.CohenT.CooperB.RobinsJ.M.MaS.JamesL.GopalakrishnaG.ChewS.K.TanC.C.SamoreM.H.et al.Transmission dynamics and control of severe acute" exact="respiratory" post="syndromeScience20033001966197010.1126/science.108661612766207 96.MoriyamaM.HugentoblerW.J.IwasakiA.Seasonality of Respiratory Viral InfectionsAnnu. Rev. Virol.20201010.1146/annurev-virology-012420-02244532196426 97.GuoQ.HuangR.ZhuangL.ZhangK.Assessment"/>
 <result pre="dynamics and control of severe acute respiratory syndromeScience20033001966197010.1126/science.108661612766207 96.MoriyamaM.HugentoblerW.J.IwasakiA.Seasonality of" exact="Respiratory" post="Viral InfectionsAnnu. Rev. Virol.20201010.1146/annurev-virology-012420-02244532196426 97.GuoQ.HuangR.ZhuangL.ZhangK.Assessment of Chinaâ€™s Offshore Wind"/>
 <result pre="and control of severe acute respiratory syndromeScience20033001966197010.1126/science.108661612766207 96.MoriyamaM.HugentoblerW.J.IwasakiA.Seasonality of Respiratory" exact="Viral" post="InfectionsAnnu. Rev. Virol.20201010.1146/annurev-virology-012420-02244532196426 97.GuoQ.HuangR.ZhuangL.ZhangK.Assessment of Chinaâ€™s Offshore Wind Resources"/>
 <result pre="of Chinaâ€™s Offshore Wind Resources Based on the Integration of" exact="Multiple" post="Satellite Data and Meteorological DataRemote Sens.201911268010.3390/rs11222680 98.WangJ.TangK.FengK.LinX.LvW.ChenK.WangF.High Temperature and"/>
 <result pre="429 citiesMedRxiv202010.1101/2020.02.22.20025791 100.Bannister-TyrrellM.MeyerA.FaverjonC.CameronA.Preliminary evidence that higher temperatures are associated with" exact="lower" post="incidence of COVID-19, for cases reported globally up to"/>
 <result pre="new cases and new deaths of COVID-19 in 166 countriesSci." exact="Total" post="Environ.202072913905110.1016/j.scitotenv.2020.13905132361460 102.ScafettaN.Distribution of the SARS-CoV-2 Pandemic and Its Monthly"/>
 <result pre="using Sentinel-1 satellite: A review and a case study on" exact="Mediterranean" post="islandsRenew. Sustain. Energy Rev.201910949951310.1016/j.rser.2019.04.059 105.WangY.WangY.ChenY.QinQ.Unique epidemiological and clinical features"/>
 <result pre="epidemiological and clinical features of the emerging 2019 novel coronavirus" exact="pneumonia" post="(COVID-19) implicate special control measuresJ. Med. Virol.20201010.1002/jmv.2574832134116 106.LiQ.GuanX.WuP.WangX.ZhouL.TongY.RenR.LeungK.LauE.WongJ.Y.et al.Early"/>
 <result pre="al.Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected" exact="Pneumonia" post="in Wuhan, ChinaJAMA20203231061106910.1001/jama.2020.1585 108.KannanS.Shaik Syed AliP.SheezaA.HemalathaK.COVID-19 (Novel Coronavirus 2019)"/>
 <result pre="patients infected with 2019 novel coronavirus in Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 114.ZhouZ.GuoD.LiC.FangZ.ChenL.YangR.LiX.ZengW.Coronavirus" exact="disease" post="2019: Initial chest CT findingsEur. Radiol.2020304398440610.1007/s00330-020-06816-732211963 115.LeiJ.LiJ.LiX.QiX.CT Imaging of"/>
 <result pre="2019 novel coronavirus in Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 114.ZhouZ.GuoD.LiC.FangZ.ChenL.YangR.LiX.ZengW.Coronavirus disease 2019: Initial" exact="chest" post="CT findingsEur. Radiol.2020304398440610.1007/s00330-020-06816-732211963 115.LeiJ.LiJ.LiX.QiX.CT Imaging of the 2019 Novel"/>
 <result pre="115.LeiJ.LiJ.LiX.QiX.CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) PneumoniaRadiology20202951810.1148/radiol.202020023632003646 116.SalehiS.AbediA.BalakrishnanS.GholamrezanezhadA.Coronavirus" exact="Disease" post="2019 (COVID-19): A Systematic Review of Imaging Findings in"/>
 <result pre="919 PatientsAJR Am. J. Roentgenol.20201710.2214/AJR.20.2367232478611 117.KimJ.ThomsenT.SellN.GoldsmithA.J.Abdominal and testicular pain: An" exact="atypical" post="presentation of COVID-19Am. J. Emerg. Med.2020381542.e11542.e310.1016/j.ajem.2020.03.05232273141 118.TayH.S.HarwoodR.Atypical presentation of"/>
 <result pre="frail older personAge Ageing202010.1093/ageing/afaa06832315386 119.LiT.Diagnosis and clinical management of severe" exact="acute" post="respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: An operatioal recommendation"/>
 <result pre="older personAge Ageing202010.1093/ageing/afaa06832315386 119.LiT.Diagnosis and clinical management of severe acute" exact="respiratory" post="syndrome Coronavirus 2 (SARS-CoV-2) infection: An operatioal recommendation of"/>
 <result pre="personAge Ageing202010.1093/ageing/afaa06832315386 119.LiT.Diagnosis and clinical management of severe acute respiratory" exact="syndrome" post="Coronavirus 2 (SARS-CoV-2) infection: An operatioal recommendation of Peking"/>
 <result pre="Peking Union Medical College Hospital (V2.0)Emerg. Microbes Infect.2020958258510.1080/22221751.2020.173526532172669 120.ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.SiH.R.ZhuY.LiB.HuangC.L.et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="GroupThe Allplex 2019-nCoV (Seegene) assay: Which performances are for SARS-CoV-2" exact="infection" post="diagnosis? [published online ahead of print, 28 May 2020]Eur."/>
 <result pre="Clin. Microbiol. Infect. Dis.20201010.1007/s10096-020-03930-8 125.YangY.YangM.ShenC.WangF.YuanJ.LiJ.ZhangM.WangZ.XingL.WeiJ.et al.Evaluating the accuracy of different" exact="respiratory" post="specimens in the laboratory diagnosis and monitoring the viral"/>
 <result pre="different respiratory specimens in the laboratory diagnosis and monitoring the" exact="viral" post="shedding of 2019-nCoV infectionsMedRxiv202010.1101/2020.02.11.20021493 126.BinnickerM.J.Emergence of a Novel Coronavirus"/>
 <result pre="viral shedding of 2019-nCoV infectionsMedRxiv202010.1101/2020.02.11.20021493 126.BinnickerM.J.Emergence of a Novel Coronavirus" exact="Disease" post="(COVID-19) and the Importance of Diagnostic Testing: Why Partnership"/>
 <result pre="Partnership between Clinical Laboratories, Public Health Agencies, and Industry Is" exact="Essential" post="to Control the OutbreakClin. Chem.20206666466610.1093/clinchem/hvaa07132077933 127.MerindolN.PÃ©pinG.MarchandC.RheaultM.PetersonC.PoirierA.HouleC.GermainH.DanyloA.SAS-CoV-2 detection by direct"/>
 <result pre="extractionJ. Clin. Virol.202012810442310.1016/j.jcv.2020.10442332416598 128.ShiH.HanX.JiangN.CaoY.AlwalidO.GuJ.FanY.ZhengC.Radiological findings from 81 patients with COVID-19" exact="pneumonia" post="in Wuhan, China: A descriptive studyLancet Infect. Dis.20202042543410.1016/S1473-3099(20)30086-432105637 129.YangQ.LiuQ.XuH.LuH.LiuS.LiH.Imaging"/>
 <result pre="Wuhan, China: A descriptive studyLancet Infect. Dis.20202042543410.1016/S1473-3099(20)30086-432105637 129.YangQ.LiuQ.XuH.LuH.LiuS.LiH.Imaging of coronavirus" exact="disease" post="2019: A Chinese expert consensus statementEur. J. Radiol.202012710900810.1016/j.ejrad.2020.10900832335426 130.PanF.YeT.SunP.GuiS.LiangB.LiL.ZhengD.WangJ.HeskethR.L.YangL.et"/>
 <result pre="of Lung Changes at Chest CT during Recovery from Coronavirus" exact="Disease" post="2019 (COVID-19)Radiology202029571572110.1148/radiol.202020037032053470 131.PanY.GuanH.ZhouS.WangY.LiQ.ZhuT.HuQ.XiaL.Initial CT findings and temporal changes in"/>
 <result pre="findings and temporal changes in patients with the novel coronavirus" exact="pneumonia" post="(2019-nCoV): A study of 63 patients in Wuhan, ChinaEur."/>
 <result pre="Radiol.2020303306330910.1007/s00330-020-06731-x32055945 132.AiT.YangZ.HouH.ZhanC.ChenC.LvW.TaoQ.SunZ.XiaL.Correlation of Chest CT and RT-PCR Testing in Coronavirus" exact="Disease" post="2019 (COVID-19) in China: A Report of 1014 CasesRadiology2020296E32E4010.1148/radiol.202020064232101510"/>
 <result pre="for medical imaging of the lungs of patients with coronavirus" exact="disease" post="2019Diagn. Interv. Radiol.202010.5152/dir.2019.2029432436845 135.HuL.WangC.Radiological role in the detection, diagnosis"/>
 <result pre="role in the detection, diagnosis and monitoring for the coronavirus" exact="disease" post="2019 (COVID-19)Eur. Rev. Med. Pharmacol. Sci.2020244523452810.26355/eurrev_202004_2103532373990 136.LiX.ZengW.LiX.ChenH.ShiL.LiX.XiangH.CaoY.ChenH.LiuC.et al.CT imaging"/>
 <result pre="Med. Pharmacol. Sci.2020244523452810.26355/eurrev_202004_2103532373990 136.LiX.ZengW.LiX.ChenH.ShiL.LiX.XiangH.CaoY.ChenH.LiuC.et al.CT imaging changes of corona virus" exact="disease" post="2019 (COVID-19): A multi-center study in Southwest ChinaJ. Transl."/>
 <result pre="Coronavirus (2019-nCoV)Radiology202029520220710.1148/radiol.202020023032017661 138.LuoL.LuoZ.JiaY.ZhouC.HeJ.LyuJ.ShenX.CT differential diagnosis of COVID-19 and non-COVID-19 in" exact="symptomatic" post="suspects: A practical scoring methodBMC Pulm. Med.2020201910.1186/s12890-020-1170-631900129 139.LongQ.X.LiuB.Z.DengH.J.WuG.C.DengK.ChenY.K.LiaoP.QiuJ.F.LinY.CaiX.F.et al.Antibody"/>
 <result pre="application of a rapid IgM-IgG combined antibody test for SARS-CoV-2" exact="infection" post="diagnosisJ. Med. Virol.20201010.1002/jmv.25727 141.KohmerN.WesthausS.RÃ¼hlC.CiesekS.RabenauH.F.Brief clinical evaluation of six high-throughput"/>
 <result pre="142.GuoL.RenL.YangS.XiaoM.ChangD.YangF.Dela CruzC.S.WangY.WuC.XiaoY.et al.Profiling Early Humoral Response to Diagnose Novel Coronavirus" exact="Disease" post="(COVID-19)Clin. Infect. Dis.202010.1093/cid/ciaa310 143.MaH.ZengW.HeH.ZhaoD.JiangD.ZhouP.ChengL.LiY.MaX.JinT.Serum IgA, IgM, and IgG responses"/>
 <result pre="and IgG responses in COVID-19Cell. Mol. Immunol.202010.1038/s41423-020-0474-z 144.DiaoB.WenK.ChenJ.LiuY.YuanZ.HanC.ChenJ.PanY.ChenL.DanY.et al.Diagnosis of" exact="Acute" post="Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid"/>
 <result pre="IgG responses in COVID-19Cell. Mol. Immunol.202010.1038/s41423-020-0474-z 144.DiaoB.WenK.ChenJ.LiuY.YuanZ.HanC.ChenJ.PanY.ChenL.DanY.et al.Diagnosis of Acute" exact="Respiratory" post="Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid ProteinmedRxiv202010.1101/2020.03.07.20032524"/>
 <result pre="responses in COVID-19Cell. Mol. Immunol.202010.1038/s41423-020-0474-z 144.DiaoB.WenK.ChenJ.LiuY.YuanZ.HanC.ChenJ.PanY.ChenL.DanY.et al.Diagnosis of Acute Respiratory" exact="Syndrome" post="Coronavirus 2 Infection by Detection of Nucleocapsid ProteinmedRxiv202010.1101/2020.03.07.20032524 145.PillaiyarT.MeenakshisundaramS.ManickamM.Recent"/>
 <result pre="Mol. Immunol.202010.1038/s41423-020-0474-z 144.DiaoB.WenK.ChenJ.LiuY.YuanZ.HanC.ChenJ.PanY.ChenL.DanY.et al.Diagnosis of Acute Respiratory Syndrome Coronavirus 2" exact="Infection" post="by Detection of Nucleocapsid ProteinmedRxiv202010.1101/2020.03.07.20032524 145.PillaiyarT.MeenakshisundaramS.ManickamM.Recent discovery and development"/>
 <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatmentBiosci. Trends20201646810.5582/bst.2020.0103032037389 154.GrahamR.L.DonaldsonE.F.BaricR.S.A"/>
 <result pre="spike proteinCell. Mol. Immunol.20201776576710.1038/s41423-020-0374-232047258 165.XiaS.LiuM.WangC.XuW.LanQ.FengS.QiF.BaoL.DuL.LiuS.et al.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
 <result pre="Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging" exact="Infectious" post="DiseasesPLoS ONE201510e014447510.1371/journal.pone.014447526641892 167.XieQ.HeX.YangF.LiuX.LiY.LiuY.YangZ.YuJ.ZhangB.ZhaoW.Analysis of the Genome Sequence and Prediction"/>
 <result pre="DiseasesPLoS ONE201510e014447510.1371/journal.pone.014447526641892 167.XieQ.HeX.YangF.LiuX.LiY.LiuY.YangZ.YuJ.ZhangB.ZhaoW.Analysis of the Genome Sequence and Prediction of" exact="B-Cell" post="Epitopes of the Envelope Protein of Middle East Respiratory"/>
 <result pre="Genome Sequence and Prediction of B-Cell Epitopes of the Envelope" exact="Protein" post="of Middle East Respiratory Syndrome-CoronavirusIEEE/ACM Trans. Comput. Biol. Bioinform.2018151344135010.1109/TCBB.2017.270258828574363"/>
 <result pre="of B-Cell Epitopes of the Envelope Protein of Middle East" exact="Respiratory" post="Syndrome-CoronavirusIEEE/ACM Trans. Comput. Biol. Bioinform.2018151344135010.1109/TCBB.2017.270258828574363 168.HoffmannM.Kleine-WeberH.SchroederS.KrÃ¼gerN.HerrlerT.ErichsenS.SchiergensT.S.HerrlerG.WuN.H.NitscheA.et al.SARS-CoV-2 Cell Entry"/>
 <result pre="by a Clinically Proven Protease InhibitorCell2020181271280.e810.1016/j.cell.2020.02.05232142651 169.InoueY.TanakaN.TanakaY.InoueS.MoritaK.ZhuangM.HattoriT.SugamuraK.Clathrin-dependent entry of severe" exact="acute" post="respiratory syndrome coronavirus into target cells expressing ACE2 with"/>
 <result pre="a Clinically Proven Protease InhibitorCell2020181271280.e810.1016/j.cell.2020.02.05232142651 169.InoueY.TanakaN.TanakaY.InoueS.MoritaK.ZhuangM.HattoriT.SugamuraK.Clathrin-dependent entry of severe acute" exact="respiratory" post="syndrome coronavirus into target cells expressing ACE2 with the"/>
 <result pre="Clinically Proven Protease InhibitorCell2020181271280.e810.1016/j.cell.2020.02.05232142651 169.InoueY.TanakaN.TanakaY.InoueS.MoritaK.ZhuangM.HattoriT.SugamuraK.Clathrin-dependent entry of severe acute respiratory" exact="syndrome" post="coronavirus into target cells expressing ACE2 with the cytoplasmic"/>
 <result pre="caveolae-independent endocytic pathwayCell Res.20081829030110.1038/cr.2008.1518227861 171.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 172.NeveuG.Ziv-AvA.Barouch-BentovR.BerkermanE.MulhollandJ.EinavS.AP-2-associated protein kinase 1 and cyclin G-associated"/>
 <result pre="endocytic pathwayCell Res.20081829030110.1038/cr.2008.1518227861 171.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 172.NeveuG.Ziv-AvA.Barouch-BentovR.BerkermanE.MulhollandJ.EinavS.AP-2-associated protein kinase 1 and cyclin G-associated kinase"/>
 <result pre="diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 172.NeveuG.Ziv-AvA.Barouch-BentovR.BerkermanE.MulhollandJ.EinavS.AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate" exact="hepatitis C" post="virus entry and are potential drug targetsJ. Virol.2015894387440410.1128/JVI.02705-1425653444 173.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects"/>
 <result pre="and are potential drug targetsJ. Virol.2015894387440410.1128/JVI.02705-1425653444 173.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: An old drug against todayâ€™s diseases?Lancet Infect. Dis.2003372272710.1016/S1473-3099(03)00806-514592603"/>
 <result pre="of Optimized Dosing Design of Hydroxychloroquine for the Treatment of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa23732150618 175.SheahanT.P.SimsA.C.LeistS.R.SchÃ¤ferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.et"/>
 <result pre="Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa23732150618 175.SheahanT.P.SimsA.C.LeistS.R.SchÃ¤ferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.et al.Comparative"/>
 <result pre="Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa23732150618 175.SheahanT.P.SimsA.C.LeistS.R.SchÃ¤ferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.et al.Comparative therapeutic"/>
 <result pre="Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa23732150618 175.SheahanT.P.SimsA.C.LeistS.R.SchÃ¤ferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.et al.Comparative therapeutic efficacy"/>
 <result pre="other drug repurposing candidatesF1000Research2020912910.12688/f1000research.22457.232194944 178.MartinezM.A.Compounds with Therapeutic Potential against Novel" exact="Respiratory" post="2019 CoronavirusAntimicrob. Agents Chemother.20206410.1128/AAC.00399-20 179.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and chloroquine effectively inhibit"/>
 <result pre="other RNA virusesCell Res.20203018919010.1038/s41422-020-0290-032071427 181.ZhaL.LiS.PanL.TefsenB.LiY.FrenchN.ChenL.YangG.VillanuevaE.V.Corticosteroid treatment of patients with coronavirus" exact="disease" post="2019 (COVID-19)Med. J. Aust.202021241642010.5694/mja2.5057732266987 182.ZhouW.LiuY.TianD.WangC.WangS.ChengJ.HuM.FangM.GaoY.Potential benefits of precise corticosteroids"/>
 <result pre="Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infectionsmedRxiv202010.1101/2020.04.23.20076612 185.FuY.ChengY.WuY.Understanding SARS-CoV-2-Mediated" exact="Inflammatory" post="Responses: From Mechanisms to Potential Therapeutic Tools. [published online"/>
 <result pre="Virol.20209281481810.1002/jmv.2580132253759 188.MichotJ.M.AlbigesL.ChaputN.SaadaV.PommeretF.GriscelliF.BalleyguierC.BesseB.MarabelleA.NetzerF.et al.Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related" exact="respiratory" post="failure: A case reportAnn. Oncol.20203196196410.1016/j.annonc.2020.03.30032247642 189.ZhangX.SongK.TongF.FeiM.GuoH.LuZ.WangJ.ZhengC.First case of COVID-19"/>
 <result pre="reportAnn. Oncol.20203196196410.1016/j.annonc.2020.03.30032247642 189.ZhangX.SongK.TongF.FeiM.GuoH.LuZ.WangJ.ZhengC.First case of COVID-19 in a patient with" exact="multiple myeloma" post="successfully treated with tocilizumabBlood Adv.202041307131010.1182/bloodadvances.202000190732243501 190.MaranoG.VaglioS.PupellaS.FaccoG.CatalanoL.LiumbrunoG.M.GrazziniG.Convalescent plasma: New evidence"/>
 <result pre="Oncol.20203196196410.1016/j.annonc.2020.03.30032247642 189.ZhangX.SongK.TongF.FeiM.GuoH.LuZ.WangJ.ZhengC.First case of COVID-19 in a patient with multiple" exact="myeloma" post="successfully treated with tocilizumabBlood Adv.202041307131010.1182/bloodadvances.202000190732243501 190.MaranoG.VaglioS.PupellaS.FaccoG.CatalanoL.LiumbrunoG.M.GrazziniG.Convalescent plasma: New evidence"/>
 <result pre="immune antagonismEmerg. Microbes Infect.2018711510.1038/s41426-018-0031-329323102 195.KhouryM.CuencaJ.CruzF.F.FigueroaF.E.RoccoP.WeissD.J.Current status of cell-based therapies for" exact="respiratory" post="virus infections: Applicability to COVID-19Eur. Respir. J.202055200085810.1183/13993003.00858-202032265310 196.ConnickP.KolappanM.CrawleyC.WebberD.J.PataniR.MichellA.W.DuM.Q.LuanS.L.AltmannD.R.ThompsonA.J.et al.Autologous"/>
 <result pre="J.202055200085810.1183/13993003.00858-202032265310 196.ConnickP.KolappanM.CrawleyC.WebberD.J.PataniR.MichellA.W.DuM.Q.LuanS.L.AltmannD.R.ThompsonA.J.et al.Autologous mesenchymal stem cells for the treatment of" exact="secondary" post="progressive multiple sclerosis: An open-label phase 2a proof-of-concept studyLancet"/>
 <result pre="1 clinical trialLancet Respir. Med.20153243210.1016/S2213-2600(14)70291-725529339 198.BariE.FerrarottiI.SaracinoL.PerteghellaS.TorreM.L.CorsicoA.G.Mesenchymal Stromal Cell Secretome for" exact="Severe" post="COVID-19 Infections: Premises for the Therapeutic UseCells2020992410.3390/cells9040924 199.HashmiS.AhmedM.MuradM.H.LitzowM.R.AdamsR.H.BallL.M.PrasadV.K.KebriaeiP.RingdenO.Survival after"/>
 <result pre="Therapeutic UseCells2020992410.3390/cells9040924 199.HashmiS.AhmedM.MuradM.H.LitzowM.R.AdamsR.H.BallL.M.PrasadV.K.KebriaeiP.RingdenO.Survival after mesenchymal stromal cell therapy in steroid-refractory" exact="acute" post="graft-versus-host disease: Systematic review and meta-analysisLancet Haematol.20163e45e5210.1016/S2352-3026(15)00224-026765648 200.XuJ.Therapeutic Applications"/>
 <result pre="graft-versus-host disease: Systematic review and meta-analysisLancet Haematol.20163e45e5210.1016/S2352-3026(15)00224-026765648 200.XuJ.Therapeutic Applications of" exact="Mesenchymal" post="Stem Cells for Systemic Lupus ErythematosusAdv. Exp. Med. Biol.20181089738510.1007/5584_2018_21229767288"/>
 <result pre="and meta-analysisLancet Haematol.20163e45e5210.1016/S2352-3026(15)00224-026765648 200.XuJ.Therapeutic Applications of Mesenchymal Stem Cells for" exact="Systemic" post="Lupus ErythematosusAdv. Exp. Med. Biol.20181089738510.1007/5584_2018_21229767288 201.GalipeauJ.SensÃ©bÃ©L.Mesenchymal Stromal Cells: Clinical"/>
 <result pre="meta-analysisLancet Haematol.20163e45e5210.1016/S2352-3026(15)00224-026765648 200.XuJ.Therapeutic Applications of Mesenchymal Stem Cells for Systemic" exact="Lupus" post="ErythematosusAdv. Exp. Med. Biol.20181089738510.1007/5584_2018_21229767288 201.GalipeauJ.SensÃ©bÃ©L.Mesenchymal Stromal Cells: Clinical Challenges"/>
 <result pre="in regulating immune responsesCell Death Differ.2012191505151310.1038/cdd.2012.2622421969 205.LengZ.ZhuR.HouW.FengY.YangY.HanQ.ShanG.MengF.DuD.WangS.et al.Transplantation of ACE2-" exact="Mesenchymal" post="Stem Cells Improves the Outcome of Patients with COVID-19"/>
 <result pre="PneumoniaAging Dis.20201121622810.14336/AD.2020.022832257537 206.ChenJ.HuC.ChenL.TangL.ZhuY.XuX.ChenL.GaoH.LuX.YuL.et al.Clinical study of mesenchymal stem cell treating" exact="acute" post="respiratory distress syndrome induced by epidemic Influenza A (H7N9)"/>
 <result pre="Dis.20201121622810.14336/AD.2020.022832257537 206.ChenJ.HuC.ChenL.TangL.ZhuY.XuX.ChenL.GaoH.LuX.YuL.et al.Clinical study of mesenchymal stem cell treating acute" exact="respiratory" post="distress syndrome induced by epidemic Influenza A (H7N9) infection,"/>
 <result pre="al.Clinical study of mesenchymal stem cell treating acute respiratory distress" exact="syndrome" post="induced by epidemic Influenza A (H7N9) infection, a hint"/>
 <result pre="and rapid translational developmentEBioMedicine20205510274310.1016/j.ebiom.2020.10274332249203 212.BalmertS.C.CareyC.D.FaloG.D.SethiS.K.ErdosG.KorkmazE.FaloL.D.Jr.Dissolving undercut microneedle arrays for multicomponent" exact="cutaneous" post="vaccinationJ. Control. Release202031733634610.1016/j.jconrel.2019.11.02331756393 213.ZhaoX.BirchallJ.C.CoulmanS.A.TatovicD.SinghR.K.WenL.WongF.S.DayanC.M.HannaS.J.Microneedle delivery of autoantigen for immunotherapy"/>
 <result pre="vaccinationJ. Control. Release202031733634610.1016/j.jconrel.2019.11.02331756393 213.ZhaoX.BirchallJ.C.CoulmanS.A.TatovicD.SinghR.K.WenL.WongF.S.DayanC.M.HannaS.J.Microneedle delivery of autoantigen for immunotherapy in" exact="type 1" post="diabetesJ. Control. Release201622317818710.1016/j.jconrel.2015.12.04026739548 214.KabashimaK.HondaT.GinhouxF.EgawaG.The immunological anatomy of the skinNat."/>
 <result pre="of the Skin Immune System and Compartmentalized Immune Responses in" exact="Infectious" post="DiseasesClin. Microbiol. Rev.20193210.1128/CMR.00034-1831366611 220.CohenJ.A.WuJ.KaplanD.H.Neuronal Regulation of Cutaneous ImmunityJ. Immunol.202020426427010.4049/jimmunol.190110931907268"/>
 <result pre="Immune Responses in Infectious DiseasesClin. Microbiol. Rev.20193210.1128/CMR.00034-1831366611 220.CohenJ.A.WuJ.KaplanD.H.Neuronal Regulation of" exact="Cutaneous" post="ImmunityJ. Immunol.202020426427010.4049/jimmunol.190110931907268 221.DicksM.D.SpencerA.J.EdwardsN.J.WadellG.BojangK.GilbertS.C.HillA.V.CottinghamM.G.A novel chimpanzee adenovirus vector with low"/>
 <result pre="and cellular immune responses in miceVaccine2017353780378810.1016/j.vaccine.2017.05.03228579232 223.SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic Treatments for Coronavirus" exact="Disease" post="2019 (COVID-19): A ReviewJAMA20203231824183610.1001/jama.2020.6019 Figure 1 Classic subgroup clusters"/>
 <result pre="Treatments for Coronavirus Disease 2019 (COVID-19): A ReviewJAMA20203231824183610.1001/jama.2020.6019 Figure 1" exact="Classic" post="subgroup clusters of coronaviruses within the family Coronaviridae, subfamily"/>
 <result pre="SARSr-CoV-2); sequential mutations and recombinations allow them to adapt to" exact="intermediate" post="hosts and finally humans [15]. Figure 3 Typical coronavirus"/>
 <result pre="di SanitÃ , ISS). Figure 8 Schematic representation of SARS-CoV-2" exact="infection" post="and virus-induced human immune system response. Proposed drugs directed"/>
 <result pre="endocytosis (I); molecules against SARS-CoV-2 main protease (II); molecules against" exact="viral" post="genome replication (III); CRISPR technologies targeting SARS-CoV-2 RNA genome"/>
 <result pre="and human neutralizing antibodies (VI). ACE2, angiotensin-converting enzyme 2; TMPRSS2," exact="type 2" post="transmembrane serine proteases; RdRp, RNA-dependent RNA polymerase; HR1, heptad"/>
 <result pre="replication and transcription GSK3 SARS-CoV Phosphorylate N protein and facilitate" exact="viral" post="replication hnRNPA1 SARS-CoV Regulate viral RNA synthesis Translation of"/>
 <result pre="Phosphorylate N protein and facilitate viral replication hnRNPA1 SARS-CoV Regulate" exact="viral" post="RNA synthesis Translation of structural proteins N-linked glycosylation enzymes"/>
 <result pre="main features among SARS-CoV, MERS-CoV and SARS-CoV-2 [24,76,86,88,93,94,95]. Virus Receptor" exact="Primary" post="Host Intermediate Host Incubation Period Number of Cases Number"/>
 <result pre="COVID-19 cases. Dry cough, mild fever, sore throat, nasal congestion," exact="muscle" post="pain, headache and malaise. Absence of serious symptoms like"/>
 <result pre="fever, sore throat, nasal congestion, muscle pain, headache and malaise." exact="Absence of" post="serious symptoms like dyspnea, also the absence of radiograph"/>
 <result pre="and malaise. Absence of serious symptoms like dyspnea, also the" exact="absence of" post="radiograph features. It may rapidly deteriorate into severe or"/>
 <result pre="mild pneumonia. Moderate Dry cough, tachypnea and shortness of breath." exact="Severe" post="Acute respiratory distress syndrome (ARDS), severe pneumonia, severe dyspnea,"/>
 <result pre="pneumonia. Moderate Dry cough, tachypnea and shortness of breath. Severe" exact="Acute respiratory distress syndrome" post="(ARDS), severe pneumonia, severe dyspnea, sepsis or septic shock,"/>
 <result pre="Moderate Dry cough, tachypnea and shortness of breath. Severe Acute" exact="respiratory" post="distress syndrome (ARDS), severe pneumonia, severe dyspnea, sepsis or"/>
 <result pre="cough, tachypnea and shortness of breath. Severe Acute respiratory distress" exact="syndrome" post="(ARDS), severe pneumonia, severe dyspnea, sepsis or septic shock,"/>
 <result pre="respiratory distress syndrome (ARDS), severe pneumonia, severe dyspnea, sepsis or" exact="septic shock," post="tachypnea (respiratory frequency) â‰¥ 30/min, blood oxygen saturation (SpO2)"/>
 <result pre="(respiratory frequency) â‰¥ 30/min, blood oxygen saturation (SpO2) â‰¤ 93%," exact="partial" post="pressure of arterial oxygen to fraction of inspired oxygen"/>
 <result pre="and/or lung infiltrates &amp;gt; 50% within 24 to 48 h." exact="Fever" post="can be absent or moderate. Critical In 5% of"/>
 <result pre="or moderate. Critical In 5% of all confirmed COVID-19 cases." exact="Respiratory" post="failure, septic shock, RNAemia, cardiac injury and/or multiple organ"/>
 <result pre="Critical In 5% of all confirmed COVID-19 cases. Respiratory failure," exact="septic shock," post="RNAemia, cardiac injury and/or multiple organ dysfunction or failure."/>
 <result pre="and lower-case fatality rate (0.9%) for patients without co-morbidities). Cardiovascular" exact="disease" post="(10.5%), diabetes (7.3%), respiratory disease (6.5%), hypertension (6%) and"/>
 <result pre="fatality rate (0.9%) for patients without co-morbidities). Cardiovascular disease (10.5%)," exact="diabetes" post="(7.3%), respiratory disease (6.5%), hypertension (6%) and oncological complications"/>
 <result pre="(0.9%) for patients without co-morbidities). Cardiovascular disease (10.5%), diabetes (7.3%)," exact="respiratory" post="disease (6.5%), hypertension (6%) and oncological complications (5.6%)."/>
 <result pre="for patients without co-morbidities). Cardiovascular disease (10.5%), diabetes (7.3%), respiratory" exact="disease" post="(6.5%), hypertension (6%) and oncological complications (5.6%)."/>
 <result pre="without co-morbidities). Cardiovascular disease (10.5%), diabetes (7.3%), respiratory disease (6.5%)," exact="hypertension" post="(6%) and oncological complications (5.6%)."/>
</results>
